NIO - Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today?
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Inhibikase Therapeutics (NASDAQ:IKT) stock is falling on Thursday after the company announced a registered direct offering and private placement.
Starting with the registered direct offering up 6,744,187 shares of IKT stock for a price of 86 cents each. Next comes the private placement, which includes 4,883,721 priced the same as in the direct offering.
To go along with these offerings, Inhibikase Therapeutics has approved the issuing of 11,627,908 warrants to acquire IKT stock. These warrants have an exercise price of 75 cents per share, can be exercised immediately, and expire in five years.
Inhibikase Therapeutics is expecting gross proceeds from these two offerings to come in at $10 million. It will use this money for general corporate purposes, such as funding clinical trials, product candidate development, and more.
What This Means for IKT Stock
First off, traders will note that IKT stock is seeing heavy trading volume this morning. That comes as some 351,000 shares of the stock change hands. This is already above the company’s daily average trading volume of about 256,000 shares.
Also, the drop in price makes sense as investors sell shares. This comes as the offerings increase the oustanding shares of IKT stock, which diluted current shareholders stakes in the company. That’s not something traders typically react well to.
IKT stock is down 10.5% as of Thursday morning.
Investors looking for all of the latest stock market news will want to stick around!
InvestorPlace is ready to go with all of the most recent stock coverage traders need for Thursday! Among that is what’s moving shares of Nio (NYSE:NIO), Buzzfeed (NASDAQ:BZFD), and Ocuphire Pharma (NASDAQ:OCUP) stock this morning. Investors can learn all about these topics at the links below!
More Thursday Stock Market News
- Why Is NIO Stock Up 5% Today?
- Why Is BuzzFeed (NASDAQ:BZFD) Stock Up 35% Today?
- Why Is Ocuphire Pharma (OCUP) Stock Down 20% Today?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that? InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More:?Penny Stocks — How to Profit Without Getting Scammed
More From InvestorPlace
- Buy This $5 Stock BEFORE This Apple Project Goes Live
- The Best $1 Investment You Can Make Today
- It doesn’t matter if you have $500 or $5 million. Do this now.
- Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
The post Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today? appeared first on InvestorPlace.